Drug Solutions Podcast: Outsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 1

In what instances should organizations outsource vs. insource? Determining the right outsourcing strategy is key to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility. In part one of this outsourcing series, Meg Rivers, senior editor, and John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals, discuss:

• What the biopharma industry currently tends to outsource
• Outsourcing strategies the biopharma industry should be utilizing
• Internal tasks the biopharma industry should consider outsourcing more in development and manufacturing
• What the biopharma industry should reconsider outsourcing and instead perform in-house
• What organizations are choosing not to outsource and why
• And more

Sponsor

Curia is a global contract research, development, and manufacturing organization offering products and services across the drug development spectrum to help their partners turn ideas into real-world impact—from curiosity to cure.

About the speaker

John Koleng, PhD, VP of Product Development and Manufacturing, TFF Pharmaceuticals: Koleng has co-founded several life sciences development and industrialization consultancies focused on product development, manufacturing, scale up, commercialization, and supply chain management. He has more than 20 years of experience in the pharmaceutical industry, including more than 10 years as a consultant. Koleng has been a founding member of three drug development companies that are actively developing new products. He has a diverse range of drug development experience from formulation to route of administration. He has published numerous scientific research articles and is an inventor on 16 issued US patents and pending patent applications. Koleng has worked with TFF Pharmaceuticals as a consultant and is an inventor on several provisional patent applications filed on behalf of TFF. Prior to his consulting career, Koleng was a founding member and served in various roles at PharmaForm before the company was sold to Akela Pharma, Inc. in 2007. John Koleng, Ph.D., R.Ph., VP of Product Development and Manufacturing at TFF Pharmaceuticals has a BS degree in Pharmacy (1994), and a PhD in Pharmaceutics (2002), both from the University of Texas at Austin where he currently holds an adjunct assistant professor of pharmaceutics appointment and serves on the UT College of Pharmacy Dean’s Advisory Council. He is a registered pharmacist.

About the Drug Solutions Podcast

Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.